| Identification | Back Directory | [Name]
Carotuximab | [CAS]
1268714-50-6 | [Synonyms]
Carotuximab
Carotuximab (anti-CD105)
Research Grade Carotuximab (DHD26501) |
| Hazard Information | Back Directory | [Uses]
Carotuximab (TRC105) is a IgG1 monoclonal antibody that blocks endoglin (CD105) and its downstream Smad signaling pathway. Carotuximab has immunomodulatory and antineoplastic actions[1][2]. | [in vivo]
Carotuximab (TRC105; 2 mg/kg; i.v; every 3 days; for 8 weeks) along with Decitabine results in a more durable anti-leukemic effect in acute myeloid leukemia (AML) xenografts. And also enhances reactive oxygen species (ROS) activity[2]. | Animal Model: | Female NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ; 7-8 weeks) injected with primary AML-0032 cells[2] | | Dosage: | 2 mg/kg | | Administration: | i.v; every 3 days; for 8 weeks | | Result: | Along with Decitabine resulted in a more durable anti-leukemic effect in AML xenografts. |
| [References]
[1] Katarina Tripska , et al. Monoclonal anti-endoglin antibody TRC105 (carotuximab) prevents hypercholesterolemia and hyperglycemia-induced endothelial dysfunction in human aortic endothelial cells. Front Med (Lausanne). 2022 Sep 7;9:845918. DOI:10.3389/fmed.2022.845918
[2] June Baik, et al. Therapeutic effect of TRC105 and decitabine combination in AML xenografts. Heliyon. 2020 Oct 13;6(10):e05242. DOI:10.1016/j.heliyon.2020.e05242 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
|